DHX32 Antibody

What is DHX32 and what tissue expression patterns should researchers expect?

DHX32 is a member of the DEAH subfamily of DEAD box proteins, functioning as a putative RNA helicase with an activation-dependent pattern of expression. It contains a conserved helicase domain consisting of 7-8 conserved motifs and is involved in RNA metabolism processes including transcription, mRNA splicing, and translation .

When conducting immunohistochemistry or Western blot experiments, researchers should expect positive expression in several tissues:

• Human tissues: Testis and kidney tissues show positive IHC staining

• Mouse tissues: Kidney and colon tissues demonstrate detectable protein levels

• Cell lines: A431 cells and COLO 320 cells show positive Western blot results

What are the recommended experimental conditions for DHX32 antibody applications?

For optimal experimental results with DHX32 antibody (such as Proteintech's 19808-1-AP), researchers should follow these methodological guidelines:

Western Blot (WB):

• Recommended dilution: 1:500-1:1000

• Expected molecular weight: 84 kDa, sometimes observed at 75 kDa

Immunohistochemistry (IHC):

• Recommended dilution: 1:20-1:200

• Antigen retrieval: TE buffer pH 9.0 (primary recommendation) or citrate buffer pH 6.0 (alternative)

• Protocol details: Deparaffinize sections in xylene, rehydrate in descending ethanol series, perform heat-induced antigen retrieval at 100°C for 10 min, block endogenous peroxidase with 0.3% hydrogen peroxide, and use 5% bovine serum albumin in PBS for blocking

How should DHX32 expression be quantified in immunohistochemistry experiments?

When quantifying DHX32 expression in IHC experiments, researchers should implement a standardized semi-quantitative scoring system that accounts for both staining intensity and percentage of positive cells:

Percentage of positively stained cells:

• 0 points: 0%

• 1 point: 1-10%

• 2 points: 10-50%

• 3 points: >50%

Staining intensity grading:

• 0 points: No staining

• 1 point: Weak staining

• 2 points: Moderate staining

• 3 points: Strong staining

Expression classification:

• Low expression: 0-3 total points

• High expression: 4-6 total points

To ensure objective assessment, slides should be evaluated by pathologists blinded to the clinicopathological features of the samples .

How can researchers effectively investigate DHX32's contradictory roles in different cancer types?

DHX32 exhibits context-dependent functions across cancer types, requiring methodologically rigorous approaches to investigate its role:

Contradictory findings:

• DHX32 is upregulated in colorectal cancer, breast cancer, and some hepatocellular carcinoma studies, promoting tumor progression

• DHX32 is downregulated in acute lymphoblastic leukemia

• DHX32 silencing increases liver cancer cell proliferation in some studies

Recommended research methodology:

• Employ multiple DHX32 silencing approaches (siRNA/shRNA with different targeting sequences) to rule out off-target effects

• Establish stable cell lines with both DHX32 knockdown and overexpression for comparative studies

• Perform rescue experiments to confirm phenotypic effects are directly attributable to DHX32

• Analyze DHX32 expression in relation to specific cancer subtypes and stages

• Investigate DHX32 subcellular localization, as its function may differ between nuclear and cytoplasmic compartments

What signaling pathways should be examined when studying DHX32's function in cancer progression?

Based on current research, investigators should focus on these key pathways when studying DHX32's mechanistic role:

Wnt signaling pathway:

• DHX32 silencing in colon cancer cells suppresses expression of Wnt pathway genes including WISP1, MMP7, and VEGFA

• DHX32 silencing in HCC decreases nuclear β-catenin expression, and β-catenin siRNA abrogates DHX32-mediated HCC progression

Apoptotic pathway:

• DHX32 affects expression of anti-apoptotic gene BCL2 and pro-apoptotic gene ACSL5

• DHX32 expression in T-cells correlates with c-FLIP short expression and alters response to Fas signaling

ERK/Akt signaling:

• Phosphorylated levels of ERK and Akt are upregulated in liver cancer cells with DHX32 knockdown

• CDK6 levels increase in liver cancer cells with DHX32 knockdown

Researchers should design experiments that measure these pathway components using phosphorylation-specific antibodies, subcellular fractionation techniques, and reporter assays to establish causal relationships.

What are the methodological approaches for investigating DHX32's role in therapeutic resistance?

Evidence suggests DHX32 may influence therapeutic responses, particularly to chemotherapy. Researchers should consider these methodological approaches:

• Gene deletion analysis:

  • Assess DHX32 gene deletions in chemotherapy-resistant patient samples

  • Monitor changes in DHX32 mutant allele frequency before and after treatment

• Drug sensitivity assays:

  • Establish dose-response curves for standard chemotherapeutics in cells with altered DHX32 expression

  • DHX32 overexpression has been shown to decrease susceptibility to 5-Fluorouracil in colorectal cancer cells

• Combination therapy evaluation:

  • Test whether DHX32 inhibition synergizes with standard chemotherapies

  • Investigate whether DHX32 expression levels predict response to specific therapeutic regimens

• Mutation analysis:

  • Analyze TCGA data for correlations between DHX32 mutations and treatment outcomes

  • DHX32 missense mutations have been associated with poor prognosis in myeloid and lymphocytic leukemia

How should researchers design experiments to resolve contradictory findings regarding DHX32 in liver cancer?

Current literature presents conflicting results regarding DHX32's role in liver cancer. To address these contradictions, researchers should:

• Employ multiple cell models:

  • Use diverse liver cancer cell lines (HepG2, Huh-7, and primary cells)

  • Compare results between different experimental models (2D culture, 3D spheroids, xenografts)

• Analyze context-dependent effects:

  • Investigate DHX32 function under different microenvironmental conditions

  • Examine whether DHX32's effect depends on the presence of specific growth factors or cytokines

• Assess temporal dynamics:

  • Study DHX32 expression and function at different stages of liver cancer progression

  • Compare acute versus sustained DHX32 knockdown effects

• Examine subcellular localization:

  • DHX32 function may depend on its nuclear versus cytoplasmic distribution

  • Perform fractionation studies combined with functional assays

• Clinical correlation:

  • Compare DHX32 expression between liver cancer tissues (43.4% showing high expression) and paracancerous tissues (88.7% showing high expression)

  • Correlate DHX32 expression with clinical parameters and patient outcomes

How can DHX32 antibody-based assays be standardized for potential diagnostic or prognostic applications?

To develop clinically relevant DHX32 antibody assays, researchers should consider these methodological approaches:

What methodological considerations should be prioritized when investigating DHX32's role in epithelial-mesenchymal transition (EMT)?

Given DHX32's documented involvement in EMT, researchers should employ these approaches:

• EMT marker analysis:

  • DHX32 expression has been shown to induce EMT in HCC cells

  • Silencing DHX32 reverses EMT in HCC cells

  • Monitor changes in epithelial markers (E-cadherin) and mesenchymal markers (N-cadherin, vimentin)

• Functional assays:

  • Assess migration and invasion using wound-healing and Transwell invasion assays

  • DHX32 has been shown to promote mobility of HCC cells

  • Measure adhesion properties and morphological changes

• Mechanistic investigation:

  • Examine DHX32's interaction with known EMT regulators like SNAIL, SLUG, and ZEB1

  • Investigate DHX32's effect on TGF-β signaling

• In vivo metastasis models:

  • Use animal models to assess DHX32's impact on tumor dissemination and metastatic colonization

  • DHX32 enhances tumor growth in vivo

What are the most common technical issues when using DHX32 antibodies and how can they be resolved?

Researchers may encounter several technical challenges when working with DHX32 antibodies:

• Background staining in IHC:

  • Solution: Optimize blocking conditions using 5% bovine serum albumin

  • Solution: Increase washing steps and duration

  • Solution: Titrate primary antibody concentration (test range from 1:20 to 1:200)

• Multiple bands in Western blot:

  • Expected observation: DHX32 may appear at both 84 kDa and 75 kDa

  • Solution: Use positive controls (mouse kidney tissue, A431 cells) to confirm band specificity

  • Solution: Include blocking peptide control to identify non-specific binding

• Variability between experiments:

  • Solution: Standardize tissue processing and fixation protocols

  • Solution: Include consistent positive controls across experiments

  • Solution: Perform technical replicates and normalize to housekeeping proteins

• RNA expression-protein correlation discrepancies:

  • Solution: Compare protein levels by Western blot with mRNA levels by qRT-PCR

  • Solution: Use primer pairs that specifically detect DHX32 (see Table II in reference)

  • Solution: Calculate relative expression using the 2^-ΔΔCq method normalized to GAPDH

How can researchers effectively design knockdown experiments to study DHX32 function?

Based on published approaches, researchers should consider these methodological details:

• Design of targeting sequences:

  • Multiple shRNA/siRNA sequences should be tested (examples include sh-1868 and sh-1898)

  • Validate knockdown efficiency by both Western blot and qRT-PCR

• Vector selection:

  • pLVTHM vectors have been successfully used for DHX32 RNAi

  • Include appropriate negative controls (pLVTHM-DHX32-NC)

• Validation of phenotypic effects:

  • Use multiple functional assays (MTT, EdU for proliferation)

  • Compare results across different time points (24, 48, 72, and 96 hours)

  • Confirm findings in multiple cell lines (e.g., both HepG2 and Huh-7)

• Rescue experiments:

  • Perform rescue experiments by re-expressing RNAi-resistant DHX32 constructs

  • This confirms observed phenotypes are due to DHX32 depletion rather than off-target effects